{
    "clinical_study": {
        "@rank": "122586", 
        "acronym": "DPF", 
        "arm_group": [
            {
                "arm_group_label": "fexofenadine 60 mg", 
                "arm_group_type": "Other", 
                "description": "First dose strength"
            }, 
            {
                "arm_group_label": "fexofenadine 120 mg", 
                "arm_group_type": "Other", 
                "description": "Second dose strength"
            }, 
            {
                "arm_group_label": "fexofenadine 180 mg", 
                "arm_group_type": "Other", 
                "description": "Third dose strength"
            }, 
            {
                "arm_group_label": "fexofenadine 240 mg", 
                "arm_group_type": "Other", 
                "description": "Fourth dose strength"
            }, 
            {
                "arm_group_label": "fexofenadine 360 mg", 
                "arm_group_type": "Other", 
                "description": "Fifth dose strength"
            }
        ], 
        "brief_summary": {
            "textblock": "The present study was adopted to evaluate the pharmacokinetics and dose linearity of\n      fexofenadine after oral administration."
        }, 
        "brief_title": "Dose Proportionality of Fexofenadine in Healthy Human Egyptian Volunteers", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "The present study was adopted to evaluate the pharmacokinetics and dose linearity of\n      fexofenadine after administration of single oral doses of 60 to 360 mg in an open-label,\n      five-way crossover study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 18 years old and not more than 45 healthy male volunteers\n\n          -  Actual weight no more than \u00b1 30% from ideal body weight based on sex, height, and\n             body frame\n\n          -  Who had passed all the screening parameters\n\n          -  Free of any drug exposure known to interfere with the pharmacokinetics or assay of\n             fexofenadine for at least 10 days prior to the study\n\n          -  Who had to be able to communicate effectively with study personnel, be literate, and\n             able to give consent.\n\n        Exclusion Criteria:\n\n          -  A clinically significant abnormal physical exam, medical history, or laboratory\n             studies\n\n          -  If they showed a sitting SBP of >140 or <100 mmHg, DBP > 90 or <60mm Hg, or a pulse\n             rate of > 95 or < 50 beats/min at screening\n\n          -  A history of serious intolerance, allergy, or sensitivity to fexofenadine\n\n          -  The use of any prescription drug within the previous month or use of any\n             over-the-counter medication (with the exception of acetaminophen) within the past 14\n             days\n\n          -  A history of blood dyscrasias\n\n          -  A history of alcohol or drug abuse within the past year\n\n          -  Donation of blood during the 8 weeks prior to the study or plans to donate blood\n             during or within 8 weeks of completing the study\n\n          -  Unable to tolerate vein puncture and multiple blood samplings\n\n          -  Any surgical/medical condition that might alter drug absorption, distribution,\n             metabolism, or excretion\n\n          -  Cannot follow instructions, in the opinion of the investigator."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01767272", 
            "org_study_id": "PPT2"
        }, 
        "intervention": {
            "arm_group_label": [
                "fexofenadine 60 mg", 
                "fexofenadine 120 mg", 
                "fexofenadine 180 mg", 
                "fexofenadine 240 mg", 
                "fexofenadine 360 mg"
            ], 
            "description": "fexofenadine brand name", 
            "intervention_name": "fexofenadine", 
            "intervention_type": "Drug", 
            "other_name": "Telfast"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Fexofenadine", 
                "Terfenadine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Fexofenadine", 
            "Pharmacokinetics", 
            "Bioavailability", 
            "Linearity", 
            "HPLC", 
            "Dose proportionality of fexofenadine in Egyptian volunteers"
        ], 
        "lastchanged_date": "January 10, 2013", 
        "number_of_arms": "5", 
        "official_title": "Dose Proportionality of Fexofenadine", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Egypt: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Tolerability was assessed based on changes in vital signs (temperature, blood pressure, pulse, and heart rate), measured before dosing in each period and approximately every 4 hours thereafter, and laboratory tests (hematology, biochemistry, liver function, and urinalysis), and performed at baseline and at the end of the study. In addition, a physician questioned volunteers about any adverse events occurring during the study, addressed them as necessary, and recorded them on the appropriate form. This physician was not blinded to treatment, but had no involvement in the study.", 
            "measure": "Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed for the duration of study, an expected average of 5 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01767272"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Damanhour University", 
            "investigator_full_name": "Sally Helmy, PhD, CPHQ", 
            "investigator_title": "Lecturer of Pharmaceutics, Faculty of Pharmacy", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Damanhour University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Damanhour University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}